SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018
May 31 2018 - 7:30AM
SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a
commercial-stage pharmaceutical company focused on the health
security market, today announced that Dr. Phillip L. Gomez, SIGA’s
Chief Executive Officer, will present at the Jefferies Global
Healthcare Conference at 12:30 pm ET on Friday, June 8, 2018 in New
York. Dr. Gomez will provide a corporate update and discuss the
company’s lead investigational product TPOXX®, an antiviral drug
targeting the treatment of smallpox.
To access the live webcast and a copy of the
presentation, please visit the Investor Relations section of the
Company's website, under Events & Presentations. A replay will
be available for a limited time following the presentation.
ABOUT SIGA TECHNOLOGIES,
INC.
SIGA Technologies, Inc. is a
commercial-stage pharmaceutical company focused on the health
security market. Health security comprises countermeasures for
biological, chemical, radiological and nuclear attacks (biodefense
market), vaccines and therapies for emerging infectious diseases,
and health preparedness. Our lead product is TPOXX®, also known as
tecovirimat and ST-246®, an orally administered and IV formulation
antiviral drug for the treatment of human smallpox disease caused
by variola virus. While TPOXX is not yet approved as
safe and effective by the U.S. Food & Drug Administration,
it is a novel small-molecule drug of which 2 million courses have
been delivered to the Strategic National Stockpile under Project
BioShield. For more information about SIGA, please
visit www.siga.com.
FORWARD-LOOKING STATEMENTS
This press release contains certain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended, including statements relating to the
submission and approval of TPOXX® by the FDA. Such
forward-looking statements are subject to various known and unknown
risks and uncertainties, and SIGA cautions you that any
forward-looking information provided by or on behalf
of SIGA is not a guarantee of future performance. More
detailed information about SIGA and risk factors that may
affect the realization of forward-looking statements, including the
forward-looking statements in this press release, is set forth
in SIGA's filings with the Securities and Exchange
Commission, including SIGA's Annual Report on Form 10-K
for the fiscal year ended December 31, 2017, and in other
documents that SIGA has filed with
the SEC. SIGA urges investors and security holders
to read those documents free of charge at the SEC's web
site at http://www.sec.gov. Interested parties may also obtain
those documents free of charge from SIGA. Forward-looking
statements are current only as of the date on which such statements
were made, and except for our ongoing obligations under the
United States of America federal securities laws, we undertake no
obligation to update publicly any forward-looking statements
whether as a result of new information, future events, or
otherwise.
Contacts:
Investor RelationsDavid
Carey212-867-1762dcarey@lazarpartners.com
MediaGlenn Silver 646-871-8485gsilver@lazarpartners.com
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Mar 2024 to Apr 2024
SIGA Technologies (NASDAQ:SIGA)
Historical Stock Chart
From Apr 2023 to Apr 2024